New Four-Drug cocktail aims to tackle tough myeloma

NCT ID NCT04883242

Ongoing Disease control Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a combination of four drugs—isatuximab, carfilzomib, pomalidomide, and dexamethasone—in 30 patients with multiple myeloma that has relapsed or become resistant to treatment. The goal is to see how many patients respond to this regimen. All participants have had at least one prior therapy and have received lenalidomide before.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: isatuximab, carfilzomib, pomalidomide, and dexamethasone
What this could lead to: If successful, this combination could offer a new treatment option for patients whose multiple myeloma has returned or stopped responding to prior therapies.
What could go wrong: This is a small, early-phase (phase 2) trial with only 30 participants, so results may not apply to all patients. The drug combination can cause side effects like low blood counts, infections, and heart or lung issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT MULTIPLE MYELOMA REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.